Prime Medicine Inc. has reported its financial results for the second quarter of 2025, highlighting a decrease in research and development (R&D) expenses to $41.4 million, down from $43.1 million in the same period of 2024. This reduction is attributed to the company's strategic focus on advancing its in vivo liver franchise, the deprioritization of its Chronic Granulomatous Disease (CGD) program, and a reduction in R&D personnel. General and administrative (G&A) expenses increased slightly to $13.1 million for the quarter, compared to $12.6 million in the previous year. This rise is primarily due to one-time severance payments, other employee termination-related expenses, and increased corporate legal expenses. In terms of business updates, Prime Medicine has announced positive data from two patients in a Phase 1/2 clinical trial for CGD, providing clinical proof-of-concept for Prime Editing. The company completed a follow-on offering, raising $144.2 million in gross proceeds, which extends its cash runway into 2027. Additionally, Prime Medicine secured up to $24 million in funding from the Cystic Fibrosis Foundation to further develop Prime Editors for Cystic Fibrosis. The company has also undergone a leadership transition and strategic restructuring, with Allan Reine, M.D., appointed as Chief Executive Officer. These initiatives are expected to significantly decrease operating expenses and cash burn, reducing anticipated cash needs by nearly half through 2027. Prime Medicine's financial outlook includes a projection that its pro-forma cash, cash equivalents, and investments of $259.6 million as of June 30, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements into 2027.